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Poster Session II S313were graft versus host disease (acute/chronic, grade, day of onset,
affected organ), infections, survival, relapse, day of bone marrow re-
generation and immunosuppression therapy.We found a statistically
significant association between rising levels of HLA-G during trans-
plantation and clinically relevant (grade II-IV) acute GvHD, infec-
tious events after transplantation, in particular fungal infections,
and development of chronic GvHD. Our preliminary data shows
that sHLA-G molecules are involved in several complications after
allogeneic hematopoietic cell transplantation.Bronquiolitis Obliterans- Patient Characteristics
CHARACTERISTICS N5 50
age 25 (2 – 50)
Recipient M / Donor F 20(40%)
Donor and recipient match
matched 40 (80%)
Source of stem cell
BM 46 (92%)
other (PB or CB) 4(8%)
Donor
related 45 (90%)
unrelated 5 (10%)
Diagnosis
CML 24 (48%)
AML 8 (16%)
ALL 5 (10%)
Fanconi Anemia 5 (10%)
Others 8 (16%)
Chronic GVHD onset
progressive 19 (38%)
quiescent 19 (38%)
de novo 8 (16%)422
AN IN-VIVO MODEL OF HUMAN T CELL-MEDIATED REJECTION OF ALLO-
GENEIC MISMATCHED HEMATOPOIETIC CD34 + STEM CELLS USING
NOD/SCID GNULL (NOG) MICE
Nicolini, B., Mahmud, D., Mahmud, N., Nucifora, G., Rondelli, D.
University of Illinois at Chicago
Anti-humanCD34+ cell T cell alloreactivity was previously shown
in-vitro. In this study we transplanted human CD34+ cells and allo-
geneic T cells in a NOD/SCID gnull (NOG) mouse model to evalu-
ate the occurrence of stem cell rejection in-vivo. After sublethal
irradiation NOG mice received 2105 CB CD34+ cells and alloge-
neic blood T cells at 1:0 (control), 1:2, or 1:10 CD34+ cell: T cell ra-
tio (n5 5-10 mice per group). Human cell engraftment was assessed
in the bone marrow and in the spleen 6 weeks following transplanta-
tion. Marrow engraftment of huCD45+ cells was 606 10% in con-
trol mice and included B cells (646 4%), CD34+ cells (186 1%),
CD33+ myeloid cells (76 1%), CD14+ monocytes (36 1%). In
contrast, mice that were transplanted with CD34+ cells and low
dose (1:2 ratio) or high dose (1:10 ratio) allo-T cells had only
96 2% and 36 1% huCD45+ cells, respectively, in the bone mar-
row (p5 0.01) and .98% were huCD3 +T cells. Spleen engraft-
ment of huCD45+ cells was lower (256 8%) in control mice (1:0
ratio) as compared to 666 10% and 366 11% in 1:2 and 1:10
groups, respectively (p5 0.05). However, also the spleen of mice re-
ceiving CD34+ and T cells included .98% CD3 +T cells. Among
the T cells, both in the marrow and in the spleen of mice in the
1:2 and 1:10 ratio groups, 60-70% were CD4 +CD8- cells, 22-
25% CD8 +CD4- cells, 1-3% CD56+ cells, and 2-5%
CD4 +CD25+ cells. Only in mice receiving low doses of T cells,
on average 126 6% of the T cells in the bone marrow and spleen
were CD4 + CD8+. Mice receiving high doses of T cells had acute
xenogeneic GVHD demonstrated by fur changes, reduced survival
(p5 0.02) and weight loss (p5 0.0001) compared to control mice
or mice receiving a lower dose of T cells (1:2 ratio). In-vitro mixed
leukocyte cultures with irrad CD34+ cells and allogeneic T cell re-
sponders (R) at the same ratio as in in-vivo experiments were then
performed w/wo the addition of CD4 +CD25+ regulatory T cells
(Tregs) at 1:1 or 1:5 Treg: R ratio. Since a 60% T cell suppression
was observed only with equal numbers of Tregs and allo-responders,
we are currently testing whether auto or allo Tregsmay prevent stem
cell rejection in NOG mice transplanted with CD34+ cells, alloge-
neic T cells and Tregs at 1:2:2 or 1:1:2 ratio. NOG mice represent
a useful model to study human T cell mediated bone marrow failure
or stem cell rejection and will allow us to investigate new strategies of
allogeneic transplantation with subsets of T cells or hematopoietic
stem cells.after DLI 3 (6%)
Risk characteristics
platelets less than 100.000/mm3 21 (42%)
.3 organs 27 (54%)
\1500 lymphocytes 39 (78%)
NIH global scoring
Moderate 14 (28%)
Severe 36 (72%)423
BRONCHIOLITIS OBLITERANS AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION – AN ANALYSIS OF 50 CASES OVER THIRTY YEARS AT A SIN-
GLE BRAZILIAN INSTITUTION
Vieira, A.G., Funke, V.A.M., Nunes, E.C., Setubal, D.C., Medeiros, L.,
Michels, M., Ribeiro, L., Morando, J., Bonamin, C., Nabhan, S.,
Bitencourt, M.A., Bonfim, C., Loth, G., Franco, V., Pasquini, R.,
Neto, J.Z. Hospital de Clinicas Federal University of Parana, Curitiba,
Parana, BrazilIntroduction: Bronchiolitis obliterans (BO) is a late complication of
hematopoietic stem cell transplantation (HSCT) usually associated
with chronic graft versus host disease (C-GVHD) and often fatal.
We describe here characteristics and clinical course of 50 patientsat a brazilian transplant center who developed bronchiolitis obliter-
ans as a manifestation of chronic graft versus host disease.
Patients andMethods:We searched the database and reviewed the
medical records of 1645 patients who received HSCT between 1979
and 2009, and identified 50 patients who developed BO, whose clin-
ical features and clinical course were analyzed retrospectively. The
diagnosis of BOwas determined by either the presence of an obstruc-
tive ventilatory defect on a pulmonary function test or a chest CT
showing small airways wall thickening or air trapping associated
with a typical clinical picture in the context of a patient with C-
GVHD. NIH criteria were used to define the severity of C-GVHD.
Results:TheprevalenceofBOin these30yearswas 3%.Patient char-
acteristics are summarized inTable 1.According to the severity of pul-
monary involvement 14 patients (28%) had score 1, 12 (24%) had
score 2, and 22 (44%) had score 3. Median time between transplanta-
tion and diagnosis ofC-GVHDwas 138 days (33-3738), whilemedian
time between the diagnosis of C-GVHD and the diagnosis of BOwas
77days (0 –1752).Median timebetween transplantationanddiagnosis
of BOwas 343 days (38 – 3877). Twenty-nine patients (58%) required
second-line treatment due to lack of response. The main secondary
treatments used were: thalidomide(11); azathioprine(18), tacrolimus
(7); mycophenolatemofetil (7) and photopheresis (1).Median survival
for this group was 1637 days (195 – 6102). At the time of this analysis
23 (46%) patients had died from BO related causes.
Conclusion: Bronchiolitis obliterans was a serious late complica-
tion, occurring in 3% of patients transplanted in our center over
the past 30 years. Mortality rate was high (46%) and most patients
(58%) did not respond to primary therapy. Better understanding of
the pathophysiology of C-GVHD is necessary for the development
of more effective therapeutic tools.424
PKCQ IS REQUIRED FOR ALLOREACTIVITY AND GVHD BUT NOT FOR
IMMUNE RESPONSES TOWARD LEUKEMIA AND INFECTION IN MICE
Yu, X.-Z.1, Valenzuela, J.O.1, Iclozan, C.A.1, Blazar, B.R.2,
Waller, E.K.3, Beg, A.A.1 1Moffitt Cancer Center, Tampa, FL; 2Univer-
sity of Minnesota, Minneapolis, MN; 3Emory University School of Medi-
cine, Atlanta, GA
S314 Poster Session IIWhen used as therapy for hematopoietic malignances, allogeneic
bone marrow transplantation (BMT) relies on the graft-versus leu-
kemia (GVL) effect to eradicate residual tumor cells through
immunologic mechanisms. However, graft-versus-host-disease
(GVHD) is a potentially lethal complication of allogeneic BMT.
Thus, inhibition of GVHD, while preserving GVL and protective
responses against infectious agents, can enhance the therapeutic
potential of BMT. GVHD is initiated by alloreactive donor T cells
that recognize mismatched major (MHC) and/or minor (MiHA)
histocompatibility antigens and cause severe damage to hematopoi-
etic and epithelial tissues. Protein kinase C theta (PKCq) is a key
regulator of T cell-receptor signaling. We show here that T cell
responses triggered by Listeria or following administration of anti-
gen plus microbial adjuvant are relatively well preserved in the ab-
sence of PKCq. In contrast, we demonstrate an essential
requirement for PKCq in alloreactivity and GVHD induction. Fur-
thermore, absence of PKCq raises the threshold for T cell activa-
tion, which selectively impacts alloresponses. Most importantly,
PKCq
-/- T cells retain both the ability to respond to virus infection
and induce GVL post BMT. These findings validate PKCq as
a potentially unique therapeutic target that is required for
GVHD induction but not for GVL or protective responses to
infectious agents.425
FEASIBILITY OF NIH CONSENSUS CRITERIA FOR CHRONIC GRAFT-
VERSUS-HOST DISEASE (GVHD): SUCCESSFUL EFFORTS IN ESTABLISH-
ING A MULTICENTER BRAZIL-SEATTLE COLLABORATIVE CONSORTIUM
Vigorito, A.C.1, Miranda, E.C.M.1, Bouzas, L.F.S.2, Moreira, M.R.2,3,
Silva, M.M.2, Tavares, R.C.B.2, Correa, M.P.1, Funke, V.A.M.4,
Nunes, E.C.4, Colturato, V.R.5, Pedro, A.5, de Sousa, M.P.5,
Mauad, M.5, Camacho, K.G.2, de Souza, C.V.1, Lee, S.J.6,
Flowers, M.E.D.6 1University of Campinas, Sao Paulo, Brazil; 2National
Institute of Cancer, Rio de Janeiro, Brazil; 3Federal University of Rio de
Janeiro, Brazil; 4Federal University of Parana, Curitiba, PR, Brazil;
5Amaral Carvalho Hospital, Jau, Sao Paulo, Brazil; 6Fred Hutchinson
Cancer Research Center, Seattle, WA
Advances in clinical trials for treatment of chronic GVHD have
been hampered by slow accrual of patients (pts) and by inconsistency
and limitation of historical systems for grading used prior to the 2005
NIH consensus criteria for diagnosis and classification of chronic
GVHD (Filipovich AH et al BBMT 2005;11:945-956). In an effort
to foster collaboration and expand the network for future clinical tri-
als in chronic GVHD, a Brazil-Seattle consortium was established in
2008 to conduct chronicGVHDstudies in Brazil. The Brazil-Seattle
chronic GVHD consortium included 15 multidisciplinary partici-
pants (i.e., hematopoietic cell transplant (HCT) physicians, derma-
tologist, dentist, psychiatrist, psychologist, physiotherapist and one
data manager) from 5 Brazilian institutions and two experts in
chronic GVHD from Seattle. The consortium held monthly tele-
conferences and met at least twice yearly during national and inter-
national HCT and Hematology meetings in Brazil and USA. After
training and translation of theNIH consensus criteria tools into Por-
tuguese, the group initiated a feasibility study using theNIH consen-
sus criteria after approval by each of the 5 participating centers’
institutional review boards. So far, 34 pts with NIH chronic
GVHD after allogeneic HCT in Brazil have been enrolled between
June 2006 and May 2009 and prospectively followed. Of the 34 pts
with NIH chronic GVHD, 26 (76%) met the overlap syndrome sub-
category and 8 (24%) the classic subcategory. The overall severity of
NIH chronic GVHDwas moderate in 21 pts (62%) and severe in 13
pts (38%). The median time from HCT to onset of NIH chronic
GVHD overlap syndrome subcategory was 5.9 months (2.5-10) and
from transplant to NIH chronic GVHD classic subcategory was 7.3
months (3.0-16). At a median follow up of 16.5 months, the overall
survival was 70%. At least 5 pts were enrolled from each center. In
conclusion we demonstrate the feasibility of the NIH consensus cri-
teria for the diagnosis and scoring of chronicGVHD in a prospective
Brazilian multicenter study and, more importantly, in establishing
a collaborative HCT network in Brazil that offers new opportunities
for future intervention, validation, and biomarkers clinical trials in
chronic GVHD.426
INCIDENCE OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PATIENTS
WITH ALLOGENEIC PERIPHERAL HEMATOPOIETIC STEM CELL TRANS-
PLANTATION AFTER A NON-MYELOABLATIVE CONDITIONING
Cantu, O.G.1, Gutierrez, H.1, Ruiz, G.2, Mancıas, C.1, Martınez, S.A.1,
Gonzalez, O.1, Jaime, J.C.1, Gomez, D.1 1Hospital Universitario,
Monterrey, Nuevo Leon, Mexico; 2Centro de Hematologıa y Medicina In-
terna, Puebla, Mexico
Introduction:Graft-versus-host disease (GVHD) is the most com-
mon complication of allogeneic hematopoietic cell transplantation
(alloHCT) and may affect the transplant outcome. Its incidence is
higher when the preparative regimen used is a non-myeloablative
and the stem cell’s source is peripheral blood after mobilization.
Objective: To demonstrate the 10 years incidence of GVHD in 2
Mexican transplant centers using peripheral hematopoietic stem
cell transplantation (PHSCT) in related donors after non-myeloa-
blative conditioning.
Patients andmethods:Three hundred and fifty six patients with he-
matological and non-hematological malignancies that underwent
PHSCT after non-myeloablative conditioning between October
1998 and November 2008 were included. The age ranged between
1 and 71 years (median of 29). Two hundred and nineteen patients
were men and 137 women. They received cyclosporine 4 mg/kg
per day and intramuscular methotrexate 5 mg/m2 in days +1, +3,
+5 and +11 for GVHD prophylaxis.
Results: Three hundred and fourteen (88%) patients were suc-
cessfully engrafted. One hundred and fifty six patients (49%) de-
veloped acute and/or chronic GVHD. Of this last number of
patients, 68 (44%) developed acute GVHD, 44 (28%) developed
chronic GVHD, and 44 (28%) developed both. Twenty three
percent (26) of the patients who developed acute GVHD were
grade III or IV, and 35% (31) of chronic GVHD patients pre-
sented in the extensive way. GVHD was the cause of dead in 33
patients (12%), even when immunosuppressive therapy (high
dose steroids and rituximab) was used. Last death was 24 months
ago; subsequently, alemtuzumab was included in GVHD
treatment.
Conclusion: The incidence of acute and chronic GVHD in our pa-
tients is lower than the reported in the literature, even though the
source of hematopoietic stem cells was peripheral blood. The mor-
tality rate has decreased due to the introduction of new are more ag-
gressive immunosuppressive agents like alemtuzumab.427
MOBILIZING CELLS WITH A TOLEROGENIC PHENOTYPE USING PEGY-
LATED RECOMBINANT MURINE GM-CSF: IN VITRO AND IN VIVO EFFECTS
Schroeder, M.A.1, Jonathan, R.1, Jaebok, C.1, Julie, R.K.1, Matthew, H.1,
Brian, D.2, DiPersio, J.F.1 1Washington University in Saint Louis, MO;
2Washington University in Saint Louis, MO
Granulocyte-macrophage colony stimulating factor (GM-CSF)
is a growth factor regulating proliferation and differentiation of
hematopoietic stem and progenitor cells. Murine GM-CSF
(mGM-CSF) has a very short half-life and pegylation of mGM-
CSF (peg-mGM-CSF) has been shown to prolong its half-life.
Based on our clinical observations that patients transplanted
with stem cell products mobilized by GM-CSF have a lower inci-
dence of acute GvHD, we hypothesized that peg-mGM-CSF may
be protective of acute GvHD in a MHC mismatched murine
model.
We have shown that C57/Bl6 mice treated with peg-mGM-
CSF led to increased CFU-C by 26.5 fold compared to PBS
treated mice (n5 6, 95% CI5 10.25-42.73). (ASH 2009) In
addition, we observed that peg-mGM-CSF increased
CD4 + FoxP3 + Tregs in both blood and spleen by 2 fold.
(p\0.05) (ASH 2009) This effect was sustained out to 4 days af-
ter the last dose of peg-mGM-CSF. Importantly, the function of
these peg-mGM-CSF Tregs, as measured in a MLR was found to
be equivalent to Tregs from PBS treated control mice (n5 3,
p5 0.27) (ASH 2009)
To assess the in vivo impact of peg-mGM-CSF on graft versus
host disease, we used the C57/Bl6/ Balb/c acute GvHD model.
